Skip to main content

Table 1 Patient background

From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

  

N(%)

Age, year

Median (range)

64.5 (37–78)

Sex

Male

35

(83.3)

Female

7

(16.7)

PS

0

37

(88.1)

1

5

(11.9)

MSKCC prognostic risk

Favorable

12

(28.6)

 

Intermediate

28

(66.7)

 

Poor

2

(4.8)

Histology

Clear cell

42*

(100)

Nephrectomy

Yes

42

(100)

No

0

 

Metastasis

Lung

32

(76.2)

 

Liver

5

(11.9)

 

Pancreas

5

(11.9)

 

Lymph node

4

(9.5)

 

Bone

4

(9.5)

  1. *Including one case with spindle cell components 5 %